Thursday, February 9, 2012 Last update: 4:33 PM
The Best of U.S. Company Technology News
Submit Company story ideas to FreshNews.com. See our complete guidelines.
Trade Events
ZIOPHARM Oncology, Inc.
News articles for ZIOPHARM Oncology, Inc.:
Wednesday, December 21, 2011
- ZIOPHARM Oncology to Present at the 30th Annual J.P. Morgan Healthcare ConferenceZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the upcoming 30th Annual J.P. Morgan Healthcare Conference on ... read more
Thursday, December 8, 2011
- ZIOPHARM Oncology to Present at the Oppenheimer 22nd Annual Healthcare ConferenceZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, ... read more
Wednesday, December 7, 2011
- ZIOPHARM Granted European Patent Allowance for PalifosfamideZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled “Salts of ... read more
Tuesday, November 22, 2011
- ZIOPHARM Oncology to Present at the 23rd Annual Piper Jaffray Health Care ConferenceZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 23rd Annual Piper Jaffray Health Care Conference on Tuesday, ... read more
Monday, November 21, 2011
- Preclinical Darinaparsin Study in PLoS ONE PublicationZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today the publication of a darinaparsin (Zinapar® or ZIO-101) study in the PLoS ONE, an international, peer-reviewed, open-access, online ... read more
Tuesday, November 15, 2011
- ZIOPHARM Oncology Presents New Darinaparsin Preclinical Prostate and Pancreatic Cancer Data at AACR-NCI-EORTC MeetingZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies ... read more
Monday, November 14, 2011
- ZIOPHARM Oncology Announces Promising Data from Phase 1b Study of Palifosfamide in Small Cell Lung and Other Cancers at AACR-NCI-EORTC MeetingZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today promising clinical results from an ongoing ... read more
Sunday, November 13, 2011
- ZIOPHARM Oncology Presents Preclinical Data for Darinaparsin Effect on Hedgehog Signaling Pathway in Prostate Cancer at AACR-NCI-EORTC MeetingZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of ... read more
Wednesday, November 9, 2011
- ZIOPHARM Oncology to Present at the Lazard Capital Markets 8th Annual Healthcare ConferenceZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the Lazard Capital Markets 8th Annual Healthcare Conference on ... read more
Thursday, November 3, 2011
- ZIOPHARM Reports Third Quarter Financial Results and HighlightsZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today reported financial results and key highlights for the ... read more
Friday, October 28, 2011
- ZIOPHARM Presents Promising Preclinical Pediatric Sarcoma Data with Oral and IV Palifosfamide at the 2011 CTOS/MSTS MeetingZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data ... read more
Wednesday, October 19, 2011
- ZIOPHARM Oncology to Present at the 10th Annual BIO Investor ForumZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 10th Annual BIO Investor Forum on Tuesday, October 25th, ... read more
Friday, October 14, 2011
- ZIOPHARM Oncology to Present at BioCentury’s Newsmakers in the Biotech Industry ConferenceZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the BioCentury Newsmakers in the Biotech Industry Conference on Friday, ... read more
Tuesday, September 20, 2011
- ZIOPHARM to Present at Upcoming Investor ConferencesZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that it will be presenting at the following investor conferences: JMP Securities Healthcare ConferenceTuesday, ... read more
Wednesday, September 7, 2011
- ZIOPHARM Oncology to Present at the Rodman & Renshaw Annual Global Investment ConferenceZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, ... read more
Tuesday, September 6, 2011
- ZIOPHARM Oncology Appoints Caesar J. Belbel as Executive Vice President, Chief Legal Officer and SecretaryZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has appointed Caesar J. Belbel, ... read more
Tuesday, August 30, 2011
- ZIOPHARM Oncology Announces First Patient Dosed in Phase I Study of ZIN ATI-001 in Advanced MelanomaZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, ... read more